Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection

H L Lim1, G K Lau, G L Davis

  • 1Department of Medicine, University of Florida, Gainesville.

Gastroenterology
|January 1, 1994
PubMed

Insights

Organ transmission of hepatitis C virus (HCV) caused subfulminant liver failure in a heart transplant patient. Early anti-HCV antibody tests were negative, highlighting diagnostic challenges in immunosuppressed individuals.

Area of Science:

  • Hepatology
  • Transplant Immunology
  • Virology

Background:

  • Heart transplant recipients are at risk for opportunistic infections and complications.
  • Hepatitis C virus (HCV) infection can manifest differently in immunocompromised hosts.
  • Subfulminant hepatic failure post-transplantation requires prompt diagnosis and management.

Observation:

  • A 51-year-old heart transplant recipient developed progressive cholestatic liver injury.
  • Initial investigations, including imaging and liver biopsy, mimicked large duct obstruction.
  • HCV infection was confirmed late due to initially negative anti-HCV antibody tests and high HCV RNA levels.

Findings:

  • Organ-transmitted HCV caused subfulminant hepatic failure with predominantly cholestatic features.
  • Immunosuppression masked early serological detection of HCV infection.
  • HCV RNA was detected in over 80% of hepatocytes, indicating significant viral replication.

Implications:

  • Anti-HCV antibody testing may be unreliable for diagnosing HCV in immunosuppressed transplant patients.
  • HCV should be considered in the differential diagnosis of cholestatic liver disease in transplant recipients.
  • Early and sensitive viral load testing is crucial for timely HCV diagnosis and management in this population.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...